The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 5.32
Ask: 6.50
Change: -0.29 (-4.68%)
Spread: 1.18 (22.18%)
Open: 6.20
High: 6.50
Low: 6.20
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Antiviral activity against Bird Flu

4 May 2011 07:00

RNS Number : 8547F
Synairgen plc
04 May 2011
 



 

 Press release 

Synairgen plc

('Synairgen' or the 'Company')

 

In vitro antiviral activity of IFN-beta against H5N1 ('Bird Flu')

 

Southampton, UK - 4 May 2011: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence, announces that interferon beta ('IFN-beta') is effective against H5N1 ('Bird Flu') in in vitro testing.

 

Avian influenza, commonly called 'Bird Flu', is an infectious viral disease of birds. Most avian influenza viruses do not infect humans; however some, such as H5N1, have caused serious infections in humans (mortality rate of over 50%) and are a particular concern for influenza preparedness programmes.

 

In the experiments, Synairgen's IFN-beta protected human lung cells against infection with Bird Flu (virus strain: Influenza A/Indonesia/5/2005 (H5N1)). By the end of the experiments (48 hours after infection), approximately 100 times less Bird Flu virus had been released from cells treated with IFN-beta than those without IFN-beta.

 

IFN-beta acts by boosting the body's host cells' defences, rather than targeting a particular virus type. Synairgen has previously shown IFN-beta activity against rhinovirus (the most frequent cause of the common cold), respiratory syncytial virus (RSV), seasonal influenza and H1N1 (swine flu). There are relatively few therapeutic options for the treatment of highly pathogenic influenza strains such as H5N1 'Bird Flu'. These results indicate that IFN-beta beta may represent a future therapeutic option against a broad range of both common and less common, but highly pathogenic, viral threats.

 

Synairgen's inhaled IFN-beta product for treatment of respiratory viruses in asthma patients has completed Phase I safety studies and is currently undergoing a multi-centre, multi-country Phase II proof of Concept study, for which recruitment is due to complete this autumn. In addition to asthma, Synairgen is pursuing a plan to develop inhaled IFN-beta for the Chronic Obstructive Pulmonary Disease (COPD) indication, and a preclinical trial in the influenza indication will be completed in the autumn.

 

Richard Marsden, CEO of Synairgen, commented, "These results are encouraging and show that IFN-beta has potential to be effective against a wide range of respiratory viruses, including challenging viruses such as Bird Flu. We look forward to seeing the results from the preclinical work in influenza later this year."

 

-Ends-

For further information, please contact:

 

Synairgen plc Tel: + 44 (0) 23 8051 2800

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

 

Matrix Corporate Capital Tel: + 44 (0) 20 3206 7000

Stephen Mischler

Nick Stone

 

Threadneedle Communications Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

 

Notes for editors

Facts about Bird Flu

·; Avian influenza, commonly called bird flu, is an infectious viral disease of birds.1

·; Most avian influenza viruses do not infect humans; however some, such as H5N1, have caused serious infections in people.1

·; Outbreaks of avian influenza in poultry may raise global public health concerns due to their effect on poultry populations, their potential to cause serious disease in people, and their pandemic potential.1

·; To date there have been over 550 laboratory-confirmed cases of H5N1 including over 320 deaths.2

·; H5N1 is resistant to amantadine and rimantadine due to wide spread use of these medications in the Asian poultry industry to prevent or treat avian influenza in birds. The current H5N1 infection has been sensitive to the neuraminidase inhibitors, oseltamirvir and zanamivir. Even with the use of broad-spectrum antibiotics, steroids, and neuraminidase inhibitors there has been a high mortality rate.3

References

1) http://www.who.int/mediacentre/factsheets/avian_influenza/en/index.html

 

2) http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_04_21/en/index.html updated to 21 April 2011

3) http://www.medscape.com/viewarticle/525642_6

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUPAAUPGGAW
Date   Source Headline
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial
6th Jul 20227:00 amRNSGrant of Options
30th Jun 20221:45 pmRNSResult of AGM
23rd Jun 20224:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:35 pmRNSPrice Monitoring Extension
15th Jun 20222:30 pmRNSHolding(s) in Company
9th Jun 20223:00 pmRNSExercise of Options and Total Voting Rights
6th Jun 20224:25 pmRNSPosting of Annual Report & Notice of AGM
25th May 20227:00 amRNSFull Year Results
18th May 20224:36 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSSynairgen presents at ATS 2022
25th Apr 20227:00 amRNSPresentation at ECCMID
19th Apr 20224:40 pmRNSSecond Price Monitoring Extn
19th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:10 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSynairgen to present at ATS 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.